Primary prevention of coronary heart disease. What has WOSCOPS told us and what questions remain?

Drugs

Volumn 54, Issue 1, 1997, Pages 1-8

  Maher, Vincent ^a,b   Sinfuego, Jowett ^a   Chao, Pauline ^a   Parekh, Jessica ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CLOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DEVELOPED COUNTRY; DIET; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MORBIDITY; NONHUMAN; PRIMARY PREVENTION; PUBLIC HEALTH; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

EID: 0030755865     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754010-00001     Document Type: Review

References (36)

1. Stary HC. Changes in the cells of atherosclerotic lesions as advanced lesions evolve in coronary arteries of children and young adults. In: Glagou S, Newman WP, Schaffer SA, editors. Pathobiology of the human atherosclerotic plaque. New York: Springer-Verlag, 1989: 93-106
2. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J 1985; 53: 363-73
3. Fuster V, Badimon L, Badimon J, et al. The pathogenesis of coronary artery disease and acute coronary syndromes. N Engl J Med 1992; 326: 242-50, 310-8
4. Fuster V, Lewis A. Conner Memorial Lecture: Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994; 90: 2126-46
5. Brown BG, Zhao X-Q, Sacco DE, et al. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-91
6. Giroud D, Li JMM, Urban P, et al. Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol 1992; 69: 729-32
7. Hackett D, Davies G, Maseri A. Preexisting coronary stenoses in patients with first myocardial infarction are not necessarily severe. Eur Heart J 1988; 9: 1317-23
8. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988; 12: 56-62
9. Davies MJ, Richardson PD, Woolf N, et al. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid. macrophage, and smooth muscle cell content. Br Heart J 1993; 69: 377-81
10. Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic lesions. Lancet 1989; 3: 941-4
11. Mittelman MA, Maclure M, Tofler GH. et al. Triggering of acute myocardial infarction by heavy physical exertion: prevention of triggering by regular exertion. N Engl J Med 1993; 329: 1677-83
12. Libby P. Molecular basis of the acute coronary syndromes. Circulation 1995;91: 2844-50
13. Maher VMG. Coronary atherosclerosis stabilization - an achievable goal. Atherosclerosis 1995; 118 Suppl.: S91-101
14. Thompson GR, Wilson PW. Coronary risk factors and their assessment. London: Science Press, 1992
15. Williams KJ, Tabas I. The response to retention hypothesis of early atherogenesis. Arterioscler Thromb 1995; 15: 551-61
16. Waters D, Craven TE, Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation 1993; 87: 1067-76
17. Buchwald H, Matts JP, Fitch LL, et al. Change in sequential coronary arteriograms and subsequent coronary events. JAMA 1992; 268: 1429-33
18. Wexler L, Brundage B, Crouse J, et at. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. Circulation 1996; 94: 1175-92
19. Summary of the second report of the National Cholesterol Education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults [editorial]. JAMA 1993; 269: 3015-23
20. Maher VMG, Brown BG. Lp(a) and coronary heart disease. Curr Opin Lipidol 1995; 6: 229-35
21. Maher VMG, Brown BG, Marcovina SM, et al. Effects of lowering elevated LDL cholesterol levels on the cardiovascular risk of lipoprotein (a). JAMA 1995; 274: 1771-4
22. Burchfiel CM, Laws A, Benfonts R, et al. Combined effects of HDL cholesterol, triglyceride and total cholesterol concentrations on 18-year risk of atherosclerotic disease. Circulation 1995; 92: 1395-400
23. Stewart BF, Brown BG, Zhao X-Q, et al. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low-density lipoprotein cholesterol. J Am Coll Cardiol 1994; 23: 899-906
24. Small DM, Bond MG, Waugh D, et al. Physicochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis. J Clin Invest 1984; 73: 1590-605
25. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA 1982; 2: 1465-77
26. Hjermann I, Holme I, Velve Byre K, et al. Effect of diet and smoking intervention on the incidence of coronary heart disease. Lancet 1981; 2: 1303-10
27. World Health Organization Collaborative Group. Multifactorial trial in the prevention of coronary heart disease: 3. Incidence and mortality results. Eur Heart J 1983; 4: 141-7
28. Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40: 1069-118
29. Lipids Research Clinics Program. The Lipid Research Clinics Coronary Primary Preventive Trial results: I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64
30. Frick ME, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45
31. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
32. Shepherd J. The West of Scotland Coronary Prevention Study (WOSCOPS): benefits of pravastatin therapy in compliant subjects [abstract]. Circulation 1996; 94 (8 Suppl. 1): 3155
33. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
34. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
35. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348: 1339-42
36. Davey-Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 1992; 304: 431-4